Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-09-01 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于血塞通注射剂产品新版医保目录执行的说明公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the execution of a new medical insurance catalog affecting their product sales. It discusses policy changes, market impact, and company responses. The document is relatively short (1982 characters) and does not contain financial statements or detailed financial data. It is an announcement about regulatory and policy changes impacting the company rather than a financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance documents or certifications, but rather a company announcement about policy impact. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2017-09-01 Chinese
大理辉睿药业有限公司审计报告
Audit Report / Information Classification · 95% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed auditor responsibilities, management responsibilities, and an audit opinion on the financial statements of the company for the periods ending December 31, 2016, and June 30, 2017. The content includes references to auditing standards and the auditor's opinion on the fairness of the financial statements. The document length is 936 characters, which is sufficient to contain the full audit report text rather than just an announcement. There is no indication that this is an Annual Report or a summary; it is a standalone audit report. Therefore, the document fits the category of Audit Report / Information (AR).
2017-09-01 Chinese
大理辉睿评估报告
Capital/Financing Update Classification · 95% confidence The document is a detailed asset appraisal report prepared by Beijing YaChao Appraisal Ltd. for Kunming Pharmaceutical Group Medical Commerce Co., Ltd. regarding the proposed acquisition of 60% equity in Dali Huirui Pharmaceutical Co., Ltd. The report includes an evaluation of the market value of the equity as of June 30, 2017, with detailed financial data, valuation methods (market and income approaches), audit references, and legal and regulatory bases for the appraisal. It is a comprehensive valuation report intended to provide a professional opinion on the value of the equity for acquisition purposes. This is not a general annual or quarterly financial report, nor is it a simple announcement or certification. It is a standalone valuation report related to a capital transaction (acquisition). Given the nature of the document as an asset valuation report for a proposed acquisition, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including acquisition-related valuation reports.
2017-09-01 Chinese
独立董事关于昆药集团医药商业有限公司收购大理辉睿药业有限公司60%股权评估相关事宜的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion on the acquisition of a 60% equity stake in a company, focusing on the evaluation of the appraisal agency's independence and professional capability. It references regulatory guidelines related to independent directors and securities exchange rules. The content is a formal opinion related to a specific transaction rather than a full report or announcement of voting results. It does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is a standalone audit-related opinion on an acquisition evaluation, fitting best under Audit Report / Information (AR). The document length is short but contains substantive content, not merely an announcement or certification. Therefore, the classification is AR with high confidence. FY 2024
2017-09-01 Chinese
关于昆药集团医药商业有限公司收购大理辉睿药业有限公司60%股权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of 60% equity in a company (Dali Huirui Pharmaceutical Co., Ltd.) by Kunming Pharmaceutical Group Medical Commerce Co., Ltd., a wholly owned subsidiary of Kunming Pharmaceutical Group. It includes transaction overview, parties involved, valuation and pricing details, payment terms, post-transaction management structure, performance compensation and rewards, risk analysis, and other related information. The document is a formal announcement of a capital acquisition transaction, not a financial report, earnings release, or regulatory filing. It does not contain quarterly or annual financial statements but focuses on the acquisition transaction details and terms. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2017-09-01 Chinese
董事会关于昆药集团医药商业有限公司收购大理辉睿药业有限公司60%股权评估相关事宜的审核意见
Capital/Financing Update Classification · 95% confidence The document is a board opinion regarding the evaluation of an acquisition of 60% equity in another company. It discusses due diligence, evaluation methods, and fairness of the valuation. This is related to a transaction involving acquisition of shares, but it is not a full merger filing or tender offer document. It is not an annual or interim report, nor an earnings release or audit report. The content fits best with a Capital/Financing Update (CAP) as it concerns acquisition and capital transaction evaluation. The document length is short and contains substantive content about the transaction evaluation, so it is not a mere announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2017-09-01 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.